Claim OwnershipRaising Health
Subscribed: 99,283Played: 591,233
Subscribe
© All rights reserved
Description
A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg Verdine, Fei-Fei Li, and Suchi Saria, as they explore the intricacies of these technological advancements and how they can be built and effectively delivered. Together, we can rewrite the script. Welcome to Raising Health.
139 Episodes
Reverse
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park. The Park brothers, with decades of expertise in healthcare and policy, including as EVP and COO at athenahealth (Ed) and Chief Technology Officer of the United States (Todd), started Devoted with the idea of building a healthcare model from scratch. Together, their discussion underscores the sector's urgent need for technological innovation and the game-changing role of AI.This episode was recorded live at a16z's LP Summit.
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.The discussion covers the implications of AI integration in healthcare workflows, AI as a potential catalyst for value-based care, and the potential for innovation in clinical trials. They also talk about the AI startup they each wish would walk through the door.
1Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
As any healthcare founder knows, it can be difficult to get into a room with the executives making purchase decisions for payors and providers—so we’re bringing the executives to you.This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider a good partnership.Julie and Jay also authored an in-depth guide to commercializing AI in healthcare based on these interviews, available here. All of our go-to-market playbooks are available on our Digital Health Builders page.
"There is a revolution unfolding in biotech. The confluence of new biological methods like CRISPR, virtually unlimited computational capacity, and machine learning has fundamentally transformed our ability to engineer biology for wide-ranging applications."Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.You can see a transcript of the episode and more information about Software Engineering Daily here.
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.Additional reading:Structures, functions and adaptations of the human LINE-1 protein
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.This episode, a cross-post with the a16z Podcast, draws parallels between Moore's Law and the race for "Moore's Law for DNA." Vijay discusses the density, longevity, and ubiquity of DNA, and how this could be leveraged into a data storage solution. Vijay and Steph mix technical advancements with futuristic speculation as they talk about what the future of biotech might look like.
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.Together, they delve into Julie Klapstein's rich career journey, which has spanned several decades of progress in healthcare. They also discussed building Availity, her time at MultiPlan, and the network effects undergirding both businesses. Finally, they talk about how AI could impact healthcare—for payors, providers, and the network businesses in between.
Scribe Therapeutics cofounder and CEO Benjamin Oakes, PhD, joins a16z Bio + Health founding general partner Vijay Pande.In this episode, Benjamin traces his journey from PhD student to pioneering CEO in genome editing. Benjamin discusses his early exposure to CRISPR technologies, his hands-on experience of transforming these bacterial immune systems into "genome editing scalpels," and the founding of Scribe. The conversation sheds light on the challenges of engineering these molecules, as well as the potential for life-changing therapeutics.
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.In this episode, engineer-turned-entrepreneur Josh charts his journey from SpaceX and Hyperloop to cofounding metabolic health-focused company Levels. With a relentless drive for data-led health monitoring, Josh highlights the potential of wearable tech for tracking various biomarkers. Josh, Vijay, and Daisy also discuss how AI can simplify complex wearables data into a comprehensible and actionable health profile, with the potential to democratize healthcare technology.
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.In this episode, Aly Raisman shares her quest for healthier living—physically, mentally and financially—on her journey from gymnast to a business investor. Having herself transitioned from an intensely structured routine, Aly emphasizes the need for more open conversations about mental health and financial literacy. She speaks passionately about the gap in women’s health solutions and hopes to inspire entrepreneurs to create impactful businesses. Aly’s experiences as a patient, survivor, and global figure adds a unique dimension to her perspective as an investor. This candid conversation with both Aly and Julie Yoo sheds light on Aly’s passion for more education within the investment space offering invaluable insights for entrepreneurs, particularly in biotech and healthcare.
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.Together, they talk about becoming healthcare entrepreneurs despite non-healthcare backgrounds and what they had to learn along the way. They also discuss finding product-market fit, how they track PMF using KPIs, and the evolving investor landscape as the digital health space expands and matures.Additional reading:Digital Health Builder Diaries series
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.Together, they dive into Joe’s experience working in the early days of the Covid pandemic, how he thinks about the Inflation Reduction Act’s effect on pharmaceutical R&D, and the future of AI regulation.Additional reading:Check out Joe's latest op-ed here, his own podcast here, and his Twitter account here.
Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people.Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh.
Bio Eats World is now Raising Health!Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit.Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences. This episode is drawn from the episodes we recorded in 2023 with Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit, which are linked below.This blend of expert commentary and firsthand insights explores the burgeoning impact of AI on healthcare innovation and how it's reshaping the future of health.AI and Actionable Insights for Drug Development with Daphne KollerNavigating the Future of AI with Andrew NgWhen Quantity Becomes Quality with Aviv RegevUsing AI to Take Bio Farther with Jakob Uszkoreit
Bio Eats World is now Raising Health!On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.Sean and Vijay discuss the building and growth of Omada, from the early days to now. As the cofounder of one of the original digital health companies, Sean has unique insight into the growth of both the digital health field and the changing venture capital environment. They also talk about the future of AI, how Omada is leveraging AI, and the challenges that might arise with using a technology in a caregiving environment.
Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health.In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task. As Pranav notes in the episode, the research and development process in medical AI development so far has been siloed by specialty, but generalist medical AI exists outside those siloes. If generalist medical AI is successful, it could act as a dynamic support system to a physician, almost like a medical resident.
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed 'molecular gates.' His company, Gate, is working to exploit a previously uncharted avenue in cell biology—the secretory translocon—for therapeutic intervention. This approach has the potential to combat diseases otherwise resistant to existing therapeutics.Jordi also imparts valuable insights on the power of platform-based problem-solving and team building.
Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health.The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights. Mario also discusses "benefit-less" benefit designs, where healthcare plans learn from and adapt to individual consumer patterns, at least theoretically leading to the holy grail of better health outcomes and cost savings.
Download from Google Play
Download from App Store
United States
.. v .v BB bb cc BB CC
I love it when people explain their papers.
Thanks for sharing, I found a lot of interesting information here. A really good post, very thankful and helpful that you will write many more posts like this one. https://www.indigocard.org/
Totally love the Journal Clubs. You should do more of them.
OMG 😍😍😍😍
yur
w 44e4353fdre2
quallyray SNB PARAMOUNT
I would be thankful if you tell me how I can get access to transcripts?
lol @ staunch capitalists trying to explain underfunding without dissing capitalism
It is interesting that this guy thinks aliens we encounter will be a product of darwian evolution at a time when we are giving animals and plants traits that we desire. We made super smart mice so we could watch them in a maze. They escaped into the wild. I think when we meet the aliens we will have tricked out our own genomes.
Very interesting episode. I had read Jeff's book long ago while in grad school. Looking forward to reading the new one.
Thank you all, this episode was one of my favourites. please use a medium app that guarantees a clear voice transmission, for podcasts are all on sounds and voices.
Wowzers this is some of the most hope inspiring news I've heard in this field since my microbial evolution class made me aware of just how dangerous our #antibiotic #resistance situation is #NPR #TIL
And this is why I paid the $199 USD to get my full genome sequenced from DanteLabs
theese doctor treat pain patients like lab rats. somehow doctors have a higher claim over ones life and well being than the patient himself. if you really listen to this guy you will see the arrogance of themselves. its not the doctors job to determine if one is lying or tell them they are not in pain in their opinion. if a person has a desired treatment and it improves their life who the f**k do thesr people think they are to deny them the pursuit of happiness. whos gonna hold a higher regard for your own well being... yourself? or someone else? common sense has left the building on almost every aspect of life. the opiod bullshit isnt the factual reporting from the paitents but the arrogant opinion of the "experts". people are not animals! having to get permission for medication id a form of slavery. we have this false belief that slavery is gone when in fact it has expanded. slavery... The condition in which one person is owned as property by another and is under the owner's contro
Just discovered this podcast, very excited--It's awesome!
Wow, that is brilliant!